イワモト タカユキ   Takayuki Iwamoto
  岩本 高行
   所属   川崎医科大学  医学部 臨床医学 乳腺甲状腺外科学
   職種   講師
論文種別 原著
言語種別 英語
査読の有無 査読あり
表題 Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer.
掲載誌名 正式名:Breast cancer research and treatment
略  称:Breast Cancer Res Treat
ISSNコード:15737217/01676806
掲載区分国外
巻・号・頁 125(3),pp.785-95
著者・共著者 Takayuki Iwamoto, Giampaolo Bianchini, Yuan Qi, Massimo Cristofanilli, Anthony Lucci, Wendy A Woodward, James M Reuben, Junji Matsuoka, Yun Gong, Savitri Krishnamurthy, Vicente Valero, Gabriel N Hortobagyi, Fredika Robertson, W Fraser Symmans, Lajos Pusztai, Naoto T Ueno
担当区分 筆頭著者
発行年月 2011/02
概要 The goal of this study was to determine whether gene expression differences exist between inflammatory breast cancers (IBC) and T stage-matched non-IBC patients stratified by hormone receptor and HER2 status. We used Affymetrix GeneChips to analyze 82 tumor samples (25 T4d patients, and 57 T4a-c patients) of newly diagnosed breast cancers. Genes that were differentially expressed between the IBC and non-IBC specimens were identified using the t test, and differential expression of gene sets was assessed using gene set analysis. Three distinct clinical subtypes of IBC and non-IBC were compared: ER-positive/HER2-normal, HER2-amplified, and ER-negative/HER2-normal. When we compared expression data from all IBC with all non-IBC, we found no significant differences after adjusting for multiple testing. When IBC and non-IBC tumors were compared by clinical subtype, however, significant differences emerged. Complement and immune system-related pathways were overexpressed in ER-positive/HER2-normal IBC. Protein translation and mTOR signaling were overexpressed in HER2-amplified IBC. Apoptosis-, neural-, and lipid metabolism-related pathways were overexpressed in ER-negative/HER2-normal IBC compared with non-IBC of the same receptor phenotype. In this T stage-matched case-control study, the survival curves of patients with IBC and non-IBC were similar for all three clinical subtypes. IBC tumors can be divided into molecular and clinical subtypes similar to those of non-IBC. Clinical subtypes of IBC show molecular differences compared with similar subtypes of non-IBC.
DOI 10.1007/s10549-010-1280-6
PMID 21153052